Revolution Medicines, Inc.
RVMDW- Exchange
- Nasdaq
- Industry
- Biological Products, (No Diagnostic Substances)
- SEC CIK
- 0001628171
In the last 90 days, Revolution Medicines, Inc. insiders filed 0 open-market purchases and 16 sales; 22 institutions reported holding it in 13F filings for Q2 2026, worth $104.3M in total; no superinvestor holds it.
Other share classesRVMD
Key figures
- Insider buysOpen market, last 90 days
- 0
- Insider sellsLast 90 days, $76.9M in total
- 16
- 13F holdersQ2 2026, −1 vs. previous quarter
- 22
- 13F valueReported value at the end of Q2 2026
- $104.3M
- Superinvestors holdingAt the end of Q2 2026
- 0
Price chart
Superinvestors holding RVMDW, Q2 2026
No superinvestor reported holding RVMDW at the end of Q2 2026.
Latest insider trades
Open-market purchases and sales by Revolution Medicines, Inc. insiders from Form 4, newest first.
| Filed (ET) | Trade date | Filing delay | Insider | Transaction | Shares | Avg price | Value | Holding change | Flags |
|---|---|---|---|---|---|---|---|---|---|
| Sep 24, 2026 (view filing)6:00 PM ET | Sep 22 | 2 days | Anderson Elizabeth MDirector | SSale | −10.1K | $193.04 | −$1.96M | −70.1%4.33K after | 5 lots10b5-1 |
| Sep 22, 2026 (view filing)6:00 PM ET | Sep 18 | 4 days | Mancini AnthonySee Remarks | SSale | −1.76K | $196.94 | −$347.4K | −4.2%40.4K after | 10b5-1 |
| Sep 18, 2026 (view filing)6:06 PM ET | Sep 16 | 2 days | Sandler Alan B.Chief Development Officer | SSale | −341 | $199.24 | −$67.9K | −0.6%52.9K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:05 PM ET | Sep 16 | 2 days | Mancini AnthonySee Remarks | SSale | −1.77K | $199.24 | −$353.4K | −4.0%42.1K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:04 PM ET | Sep 16 | 2 days | Kelsey Stephen MichaelSee Remarks | SSale | −5.57K | $199.24 | −$1.11M | −1.9%286.3K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:03 PM ET | Sep 16 | 2 days | Horn Margaret AChief Operating Officer | SSale | −4.97K | $199.24 | −$989.6K | −3.2%149.7K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:02 PM ET | Sep 16 | 2 days | Goldsmith Mark ASee Remarks | SSale | −14.0K | $199.24 | −$2.79M | −5.2%253.3K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:01 PM ET | Sep 16 | 2 days | Cislini JeffSVP & General Counsel | SSale | −3.37K | $199.24 | −$670.6K | −6.0%52.5K after | 2 lots10b5-1 |
| Sep 18, 2026 (view filing)6:00 PM ET | Sep 16 | 2 days | Anders JackChief Financial Officer | SSale | −4.05K | $199.24 | −$807.5K | −3.3%119.2K after | 2 lots10b5-1 |
| Sep 15, 2026 (view filing)6:00 PM ET | Sep 11 | 4 days | Kelsey Stephen MichaelSee Remarks | SSale | −92.5K | $202.36 | −$18.7M | −24.1%291.9K after | 8 lots10b5-1 |
Top 10 13F holders, Q2 2026
The largest institutional positions in Revolution Medicines, Inc. at the end of Q2 2026; share changes are against Q1 2026.
| Institution | Shares | Value | % of portfolio | Change in shares | Action |
|---|---|---|---|---|---|
| LMR Partners LLP | 5,066,598 | $47.5M | 0.35% | +1,228,574+32.0% | Added |
| D. E. Shaw & Co., Inc. | 1,580,345 | $14.9M | 0.01% | 00.0% | Unchanged |
| Sculptor Capital LP | 709,670 | $6.66M | 0.07% | −249,152−26.0% | Reduced |
| CSS LLC | 78,367 | $6.61M | 0.29% | +60,862+347.7% | Added |
| Price T Rowe Associates Inc | 579,550 | $5.45M | 0.00% | 00.0% | Unchanged |
| Caption Management, LLC | 517,685 | $4.86M | 0.17% | 00.0% | Unchanged |
| Adage Capital Partners GP, L.L.C. | 500,000 | $4.69M | 0.01% | 00.0% | Unchanged |
| Rangeley Capital, LLC | 25,000 | $4.68M | 4.35% | +25,000 | New |
| Perceptive Advisors LLC | 250,000 | $2.34M | 0.04% | 00.0% | Unchanged |
| Bleichroeder LP | 200,000 | $1.88M | 0.34% | 00.0% | Unchanged |